%0 Journal Article %A Chaoran Chen %A Sarah Nadeau %A Ivan Topolsky %A Marc Manceau %A Jana S. Huisman %A Kim Philipp Jablonski %A Lara Fuhrmann %A David Dreifuss %A Katharina Jahn %A Christiane Beckmann %A Maurice Redondo %A Christoph Noppen %A Lorenz Risch %A Martin Risch %A Nadia Wohlwend %A Sinem Kas %A Thomas Bodmer %A Tim Roloff %A Madlen Stange %A Adrian Egli %A Isabella Eckerle %A Laurent Kaiser %A Rebecca Denes %A Mirjam Feldkamp %A Ina Nissen %A Natascha Santacroce %A Elodie Burcklen %A Catharine Aquino %A Andreia Cabral de Gouvea %A Maria Domenica Moccia %A Simon GrĂ¼ter %A Timothy Sykes %A Lennart Opitz %A Griffin White %A Laura Neff %A Doris Popovic %A Andrea Patrignani %A Jay Tracy %A Ralph Schlapbach %A Emmanouil T. Dermitzakis %A Keith Harshman %A Ioannis Xenarios %A Henri Pegeot %A Lorenzo Cerutti %A Deborah Penet %A Anthony Blin %A Melyssa Elies %A Christian L. Althaus %A Christian Beisel %A Niko Beerenwinkel %A Martin Ackermann %A Tanja Stadler %T Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland %D 2021 %R 10.1101/2021.03.05.21252520 %J medRxiv %P 2021.03.05.21252520 %X Background In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now named B.1.1.7. Based on initial data from the UK and later data from other countries, this variant was estimated to have a transmission fitness advantage of around 40-80% [1, 2, 3].Aim This study aims to estimate the transmission fitness advantage and the effective reproductive number of B.1.1.7 through time based on data from Switzerland.Methods We generated whole genome sequences from 11.8% of all confirmed SARS-CoV-2 cases in Switzerland between 14 December 2020 and 11 March 2021. Based on these data, we determine the daily frequency of the B.1.1.7 variant and quantify the variant’s transmission fitness advantage on a national and a regional scale.Results We estimate B.1.1.7 had a transmission fitness advantage of 43-52% compared to the other variants circulating in Switzerland during the study period. Further, we estimate B.1.1.7 had a reproductive number above 1 from 01 January 2021 until the end of the study period, compared to below 1 for the other variants. Specifically, we estimate the reproductive number for B.1.1.7 was 1.24 [1.07-1.41] from 01 January until 17 January 2021 and 1.18 [1.06-1.30] from 18 January until 01 March 2021 based on the whole genome sequencing data. From 10 March to 16 March 2021, once B.1.1.7 was dominant, we estimate the reproductive number was 1.14 [1.00-1.26] based on all confirmed cases. For reference, Switzerland applied more non-pharmaceutical interventions to combat SARS-CoV-2 on 18 January 2021 and lifted some measures again on 01 March 2021.Conclusion The observed increase in B.1.1.7 frequency in Switzerland during the study period is as expected based on observations in the UK. In absolute numbers, B.1.1.7 increased exponentially with an estimated doubling time of around 2-3.5 weeks. To monitor the ongoing spread of B.1.1.7, our plots are available online.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTS acknowledges funding from the Swiss National Science foundation (Special Call on Coronaviruses; 31CA30_196267 and 31CA30_196348). CA received funding from the European Union Horizon 2020 research and innovation programme - project EpiPose (No 101003688).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics commission (Ethikkommission Nordwest- und Zentralschweiz) confirmed that our study is exempt from ethical oversight as it only considers viral RNA but no human data. The final letter is attached.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll used data and code are publicly available. https://github.com/cevo-public/Quantification-of-the-spread-of-a-SARS-CoV-2-variant %U https://www.medrxiv.org/content/medrxiv/early/2021/06/02/2021.03.05.21252520.full.pdf